Patients to receive new cancer drugs faster under Brexit rules shake-up

23 January 2022 - Seven medicines already approved as changes cut as much as a month off approval times. ...

Read more →

NICE moves: increased accessibility and flexibility for health tech

19 January 2022 - NICE also aims to make strides in digital, genomic and antimicrobial technologies ...

Read more →

NICE signals commitment to greater flexibility in its evaluation of promising new health technologies and making patient access fairer

20 January 2022 - Changes to the way medicines and other health technologies are evaluated by NICE for use in the ...

Read more →

UK’s NICE to launch sweeping changes to drug assessments to be faster, more agile

19 January 2022 - The health technology assessment body has been under pressure from drugmakers and patient groups for years to ...

Read more →

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations

11 January 2022 - The new CHEERS 2022 statement replaces previous CHEERS reporting guidance.  ...

Read more →

NICE recommends Rinvoq for psoriatic arthritis patients

10 January 2022 - The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination recommending ...

Read more →

NICE recommends MSD’s Keytruda in combination with chemotherapy for routine treatment of lung cancer

7 January 2022 - With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer ...

Read more →

Children and young people set to benefit from new treatment for peanut allergy

23 December 2021 - Children and young people aged between 4 and 17 with a peanut allergy could be set to ...

Read more →

Biased Outcome reporting Guidelines for Underwhelming Studies (BOGUS) statement and checklist

10 December 2021 - A light hearted article to end the year. Merry Christmas to all our readers. We will ...

Read more →

NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma

17 December 2021 - The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund. ...

Read more →

NICE recommend venetoclax and azacitidine for patients with aggressive blood cancer

16 December 2021 - Venetoclax is an oral once daily treatment, which blocks the action of the B-cell lymphoma-2 protein, ...

Read more →

NICE recommends offering PrEP to people at high risk of HIV for first time

15 December 2021 - People at the highest risk of catching HIV should be offered pre-exposure prophylaxis, NICE has recommended for ...

Read more →

NICE finally accepts use of rare cancer therapy Poteligeo

15 December 2021 - NICE has reversed its earlier decision not to recommend the use of Kyowa Kirin’s Poteligeo (mogamulizumab). ...

Read more →

NICE publish final guidance recommending Aspaveli in adults with ultra rare blood disorder

9 December 2021 - The medicine is additionally undergoing assessment with the Medicines and Healthcare products Regulatory Agency for a ...

Read more →

NICE terminates appraisal of yet another cancer medicine

7 December 2021 - NICE is unable to make a recommendation on the use of olaparib (Lynparza) on the NHS for ...

Read more →